Rakesh C Kukreja
Overview
Explore the profile of Rakesh C Kukreja including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
3955
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samidurai A, Olex A, Ockaili R, Kraskauskas D, Roh S, Kukreja R, et al.
Cells
. 2023 Dec;
12(24).
PMID: 38132140
The inhibition of mammalian target of rapamycin (mTOR) with rapamycin (RAPA) provides protection against myocardial ischemia/reperfusion (I/R) injury in diabetes. Since interactions between transcripts, including long non-coding RNA (lncRNA), microRNA(miRNA)...
2.
Samidurai A, Kukreja R
Cardiovasc Drugs Ther
. 2023 Dec;
38(3):411-413.
PMID: 38055185
No abstract available.
3.
Iness A, Shah K, Kukreja R
Mol Cell Biochem
. 2023 Sep;
479(9):2405-2414.
PMID: 37768496
Ivabradine is a pharmacologic agent that inhibits the funny current responsible for determining heart rate in the sinoatrial node. Ivabradine's clinical potential has been investigated in the context of heart...
4.
Samidurai A, Saravanan M, Ockaili R, Kraskauskas D, Lau S, Kodali V, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37240345
Robust activation of mTOR (mammalian target of rapamycin) signaling in diabetes exacerbates myocardial injury following lethal ischemia due to accelerated cardiomyocyte death with cardiac remodeling and inflammatory responses. We examined...
5.
Xi L, Kraskauskas D, Muniyan S, Batra S, Kukreja R
Am J Physiol Regul Integr Comp Physiol
. 2023 Mar;
324(4):R589-R600.
PMID: 36878484
Androgen-deprivation therapy (ADT) is the primary systemic therapy for treating advanced or metastatic prostate cancer (PCa), which has improved survival outcomes in patients with PCa. However, ADT may develop metabolic...
6.
Zhang C, Atri P, Nallasamy P, Parte S, Rauth S, Nimmakayala R, et al.
Cancer Lett
. 2022 Oct;
551:215922.
PMID: 36285687
Mucin MUC4 is an aberrantly expressed oncogene in pancreatic ductal adenocarcinoma (PDAC), yet no pharmacological inhibitors have been identified to target MUC4. Here, we adapted an in silico screening method...
7.
Samidurai A, Xi L, Das A, Kukreja R
Annu Rev Pharmacol Toxicol
. 2022 Oct;
63:585-615.
PMID: 36206989
Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger, mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is one of the 11 members of the cyclic nucleotide...
8.
Kukreja R, Wang R, Koka S, Das A, Samidurai A, Xi L
Mol Cell Biochem
. 2022 Aug;
478(3):679-696.
PMID: 36036333
Type 2 diabetes (T2D) is one of the major risk factors for developing cardiovascular disease and the resultant devastating morbidity and mortality. The key features of T2D are hyperglycemia, hyperlipidemia,...
9.
Samidurai A, Ockaili R, Cain C, Roh S, Filippone S, Kraskauskas D, et al.
STAR Protoc
. 2021 Sep;
2(3):100772.
PMID: 34485939
We developed a preclinical model of myocardial ischemia/reperfusion (I/R) injury in conscious diabetic rabbits to identify an early pharmacological intervention for patients with diabetes and acute myocardial infarction (AMI). Here,...
10.
Bhat O, Yuan X, Kukreja R, Li P
FASEB J
. 2021 Jun;
35(7):e21732.
PMID: 34143450
Acid ceramidase (murine gene code: Asah1) (50 kDa) belongs to N-terminal nucleophile hydrolase family. This enzyme is located in the lysosome, which mediates conversion of ceramide (CER) into sphingosine and...